Viewray Inc (NASDAQ:VRAY) reported that the firm obtained 510(k) approval from the U.S. FDA to commercialize the MRIdian Linac system, the firm’s advanced linear accelerator-dependent MRI-guided radiation therapy setup.
Chris A. Raanes, the CEO and President of Viewray, reported that FDA nod of the MRIdian Linac is a transformative ground-breaking company. They consider that accessibility of the world’s first commercial plan to integrate MRI for soft-tissue visualization and a solid linear accelerator will result in a new standard treatment in radiation oncology.
Experimental experience with ViewRay’s MRIdian System has shown the advantages of on-table adaptive treatment and real-time MRI projection, as clinicians are witnessing for the first time how much organs and tumors change shape and move during treatment. The initial two MRIdian Linac systems in the U.S. are projected to be executed at Henry Ford Hospital and Barnes-Jewish Hospital.
Radiation oncologists have awaited the advent of a clinical setup that combines MR-imaging and linac radiation delivery. This is a key breakthrough in enhancing the efficacy of radiation treatment for patients.
The team is proud to be included as the first centers to provider treatment with MRIdian. The ability to know what’s happening inside the human body while the subject is undergoing radiation therapy and confirm the radiation continually continues to be on target is a big leap forward and will assist them to boost patient outcomes.
With MRI-guided radiation treatment, Radiation Oncology Physics can watch the movement of organs and tumors in the human body as radiation is being offered and adapt the dosage of radiation in real-time, to assist make sure the maximum dose spreads to the tumor and that pertaining healthy tissue is spared. This technology assists team to cure tumors such those in the liver, pancreas and lung where better precision is vital due to adjacent organs and other major structures.